Therapeutic Comparison of Metformin and Sulfonylurea, Alone and in Various Combinations. A Double-Blind Controlled Study

Hermann, L. S.; Kjellström, Thomas; Scherstén, Bengt; Bitzén, Per-Olof; Lindgärde, Folke; Melander, A

doi:10.1097/00019616-199503000-00023

Cited by 48 publications

(78 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Some plants exhibit properties similar to the well-known sulfonylurea drugs like glibenclamide; they reduce blood glucose in normoglycaemic animals (Ivorra et al, 1988;Davis and Granner, 1996). Some other plants act like biguanides such as metformin which is an antihyperglycaemic compound; they do not affect blood glucose in normal state (Bailey et al, 1985;Hermann et al, 1994;De Fronzo and Goodman, 1995;Stumvoll et al, 1995). We hypothesized that AELVC could have a sulfonylurea-like mechanism since it decreased blood glucose in normoglycaemic rats such as glibenclamide.…”

Section: Discussionmentioning

confidence: 98%

Hypoglycaemic and antidiabetic activity of acetonic extract of Vernonia colorata leaves in normoglycaemic and alloxan-induced diabetic rats

Cissé

Nongonierma

et al. 2005

Journal of Ethnopharmacology

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 98%

Hypoglycaemic and antidiabetic activity of acetonic extract of Vernonia colorata leaves in normoglycaemic and alloxan-induced diabetic rats

Cissé

Nongonierma

et al. 2005

Journal of Ethnopharmacology

View full text Add to dashboard Cite

“…26 In two recent studies, glycemic control improved when the second drug was added in patients whose blood glucose concentration was inadequately controlled by treatment with one drug. 27,28 The United Kingdom Prospective Diabetes Study of 5102 patients with Type 2 diabetes showed that reducing HbA1c by 1% decreased the risk of any diabetes-related complication by 21%, death related to diabetes by 21%, myocardial infarction by 14%, and microvascular complications, including retinopathy nephropathy, and neuropathy, by 37%. 29 This shows that the reduction in HbA1c of at least 1% would be anticipated to impart a meaningful reduction in both cardiovascular and microvascular complications.…”

Section: Discussionmentioning

confidence: 99%

Evaluation of Efficacy and Tolerability of Gliclazide and Metformin Combination: A Multicentric Study in Patients With Type 2 Diabetes Mellitus Uncontrolled on Monotherapy With Sulfonylurea or Metformin

Pareek¹,

Chandurkar

Zawar

et al. 2010

American Journal of Therapeutics

View full text Add to dashboard Cite

The objective of this study was to compare the effects of gliclazide/metformin on glycemic control in patients with Type 2 diabetes mellitus uncontrolled on monotherapy with sulfonylurea or metformin. This was a prospective, open-labeled, multicentric study over 12 weeks. Patients who were diagnosed of Type 2 diabetes and were uncontrolled on monotherapy with oral hypoglycemic agents, including gliclazide and metformin, characterized by HbA1c 7% or greater and 10% or less and fasting plasma glucose (FPG) 140 mg/dL or greater were enrolled in this study. The treatment regimen was started at 80 mg gliclazide plus 500 mg metformin once a day and was titrated to the next dose level depending on the clinician's judgment, not exceeding a total daily dose of 320 mg gliclazide and 2000 mg metformin. Changes from baseline HbA1c, FPG, and postprandial glucose were examined. After 12-weeks treatment, the gliclazide + metformin combination showed improvement in metabolic control as assessed by changes in HbA1c, FPG, and postprandial glucose. The primary efficacy parameter, HbA1c, was significantly reduced to 7.35 ± 1.10 at the end of treatment from the baseline value (8.51 ± 0.77) (P < 0.001). A total of 84.35% of patients showed a 0.5% or greater reduction in HbA1c and 37.39% of patients reported less than 7% HbA1c at the end of therapy. FPG and postprandial glucose were significantly reduced at the end of therapy as compared with baseline values (P < 0.001). Moreover, the lipid profile was also improved during the treatment period. The addition of gliclazide to metformin is an effective treatment for patients inadequately controlled on sulfonylurea or metformin alone. A combination of gliclazide with metformin achieves good glycemic control and improves lipid levels with better tolerability profile.

show abstract

“…As the first-line therapy for type 2 diabetes, metformin is the most frequently used oral glucose-lowering drug in the United States [2]. However, studies suggest that metformin therapy is characterized by considerable inter-individual variability in clinical efficacy [3,4]. Over 30% patients receiving metformin monotherapy were classified as nonresponders in a UK followup study during three years [4].…”

Section: Introductionmentioning

confidence: 99%

SLC47A1 gene rs2289669 G>A variants enhance the glucose-lowering effect of metformin via delaying its excretion in Chinese type 2 diabetes patients

He¹,

Zhang²,

Lü³

et al. 2015

Diabetes Research and Clinical Practice

View full text Add to dashboard Cite

Therapeutic Comparison of Metformin and Sulfonylurea, Alone and in Various Combinations. A Double-Blind Controlled Study

Cited by 48 publications

References 0 publications

Hypoglycaemic and antidiabetic activity of acetonic extract of Vernonia colorata leaves in normoglycaemic and alloxan-induced diabetic rats

Hypoglycaemic and antidiabetic activity of acetonic extract of Vernonia colorata leaves in normoglycaemic and alloxan-induced diabetic rats

Evaluation of Efficacy and Tolerability of Gliclazide and Metformin Combination: A Multicentric Study in Patients With Type 2 Diabetes Mellitus Uncontrolled on Monotherapy With Sulfonylurea or Metformin

SLC47A1 gene rs2289669 G>A variants enhance the glucose-lowering effect of metformin via delaying its excretion in Chinese type 2 diabetes patients

Contact Info

Product

Resources

About